EICHORPublic-registry site landscape for NCT04173065, “A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH”, a NASH - Nonalcoholic Steatohepatitis study sponsored by Viking Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04173065 (registry record) |
| Study title | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH |
| Official title | VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis |
| Sponsor | Viking Therapeutics, Inc. |
| Condition(s) | NASH - Nonalcoholic Steatohepatitis |
| Phase | PHASE2 |
| Listed sites | 79 |
| Site countries | United States, Belgium, France, Mexico, Puerto Rico |
Patient-friendly overview of this study: eichor.com/study/NCT04173065.
Eichor generates a preliminary site-risk snapshot for NCT04173065 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other NASH - Nonalcoholic Steatohepatitis trials
More from Viking Therapeutics, Inc.
← Eichor home · All tracked trials · NASH - Nonalcoholic Steatohepatitis studies · Weekly briefs
